Search
Kairos Pharma Ltd
KAPAAdd to Watchlist
0.370USD
+0.004+1.06%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
7.92MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.06%
5 Days
+5.74%
1 Month
-20.58%
6 Months
-49.25%
Year to Date
-47.87%
1 Year
-43.15%
Key Figures
0.362Open
0.389High
104.50KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.49%Turnover Ratio
0.368Prev. Close
0.360Low
27.94KTurnover
LossP/E Static
1.49P/B
0.00%Div Yield TTM
-85.36%ROA
2.11052wk High
1.09Volume Ratio
-2.60MNet Profit
21.41MShares
-0.2948EPS TTM
--Beta
-93.84%ROE
0.40052wk Low
7.88%Amplitude
--Gross Margin
7.92MMarket Cap
-3.64Reward/Risk
5.76%Risk Rate
TradingKey Stock Score of Kairos Pharma Ltd
Currency: USD Updated: 2026-07-02Key Insights
Kairos Pharma Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 199 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kairos Pharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Kairos Pharma Ltd Highlights
StrengthsRisks
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -1.26, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.15M shares, decreasing 49.36% quarter-over-quarter.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
12.000
Target Price
+3159.98%
Upside Space
Kairos Pharma Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Kairos Pharma Ltd Info
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
Ticker SymbolKAPA
CompanyKairos Pharma Ltd
CEOYu (John S)
Websitehttps://kairospharma.com
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Kairos Pharma Ltd (KAPA)?
The current price of Kairos Pharma Ltd (KAPA) is 0.37.
What is the symbol of Kairos Pharma Ltd?
The ticker symbol of Kairos Pharma Ltd is KAPA.
What is the 52-week high of Kairos Pharma Ltd?
The 52-week high of Kairos Pharma Ltd is 2.11.
What is the 52-week low of Kairos Pharma Ltd?
The 52-week low of Kairos Pharma Ltd is 0.40.
What is the market capitalization of Kairos Pharma Ltd?
The market capitalization of Kairos Pharma Ltd is 7.92M.
Is Kairos Pharma Ltd (KAPA) currently rated as Buy, Hold, or Sell?
According to analysts, Kairos Pharma Ltd (KAPA) has an overall rating of Buy, with a price target of 12.00.
What is the Earnings Per Share (EPS TTM) of Kairos Pharma Ltd (KAPA)?
The Earnings Per Share (EPS TTM) of Kairos Pharma Ltd (KAPA) is -0.30.